CLX - Educational Analysis * US Equities
Educational Analysis * US Equities

CLX

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerCLX
CategoryEducational primer
Last reviewedNovember 16, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, with fiscal 2026 net sales of $6.7 billion, roughly 9,200 employees, operations in approximately 25 countries, and sales in about 95 markets. Its consumer-facing brands include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional arm sells under Purell, CloroxPro, and Clorox Healthcare. In April 2026, Clorox completed the acquisition of GOJO Industries, adding Purell and expanding its health, hygiene, and business-to-business footprint.

The company’s margin structure sits at a net margin of 9.4%, which means it converts about 9.4 cents of every sales dollar into bottom-line profit. That is a healthy but not standout margin for a branded staples business; it points to real pricing power and cost discipline, but also to the reality that manufacturing, marketing, and retailer allowances consume the majority of revenue. The most striking profitability metric, however, is ROE of -1,920.6%. A figure of that magnitude almost always reflects negative shareholders’ equity rather than a conventional profitability problem; with positive net income, the denominator in ROE has likely been driven below zero by accumulated losses, buybacks, or balance-sheet restructuring. As a result, ROE is not a useful yardstick for Clorox right now, and investors should focus on P/E, margin, cash flow, and the leverage profile instead. The beta of 0.58 is consistent with a defensive staples name whose cash flows are less correlated with the broader equity market.

Financial posture

Clorox currently trades with a market capitalization of $13.3 billion and a P/E ratio of 19.7. A 19.7x multiple is neither deep value nor aggressively expensive; it reads as the market pricing in a stable, slow-growth consumer defensive with some margin-recovery optionality. The 9.4% net margin provides the core evidence that the business remains profitable at the operating level, even if the balance-sheet equity position is unusual.

The negative ROE of -1,920.6% deserves special attention: it is not a signal of catastrophic operational losses when net margin is positive, but it does flag that shareholder equity has been eroded or restructured. In this situation, the P/E of 19.7 becomes a more relevant valuation lens than book-value-based metrics. The beta of 0.58 underlines the lower systematic risk typically associated with household-product demand.

Strategic priorities & outlook

Clorox’s most recent 10-K frames the company’s agenda around the IGNITE strategy, which has four stated pillars: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Operational execution focuses on completing and optimizing a new enterprise resource planning (ERP) system alongside a broader digital transformation, with the goal of generating long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

The recent GOJO acquisition is central to the health-and-hygiene priority: Clorox is integrating the business and pushing deeper into professional and institutional markets. At the same time, it is investing in strong brands, strategic digital capabilities, and a streamlined operating model to build what management describes as a more resilient company capable of delivering consistent, profitable growth.

The 10-K also notes that fiscal 2026 was a down year, with organic sales and earnings declining and diluted EPS falling 26%. Some of that decline was attributed to macroeconomic headwinds and the timing of the ERP transition, which had pulled some sales forward into fiscal 2025. A structural item worth watching is customer concentration: Walmart accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half of consolidated net sales. Finally, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026; Clorox purchased P&G’s 20% interest, after which Glad retained core intellectual property licenses on a royalty-free basis.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox sits in a sector defined by recurring demand, but it is still exposed to a range of macro and policy variables. Raw materials—plastics and resins for Glad bags, chemicals for disinfectants, fibers, and agricultural inputs for food and personal-care products—can move with oil, natural gas, and commodity prices. Freight, energy, and logistics costs also flow directly into the cost of goods sold, while tariffs or trade restrictions on imported inputs can squeeze margins or disrupt formulations.

Because Clorox sells into about 95 markets, currency translation is another real exposure: a stronger U.S. dollar can reduce the value of overseas revenue reported back home, while a weaker dollar can help. On the regulatory side, household and personal-care products are subject to EPA, FDA, and FTC oversight around efficacy claims, ingredient labeling, and product safety; disinfectant and healthcare-adjacent brands such as Clorox and Purell tend to face particularly close scrutiny. The industry also competes with private-label alternatives, especially when retailers are as concentrated as Clorox’s disclosures suggest, and pricing decisions can be constrained by consumer trade-down behavior during periods of high inflation.

Recent developments

The most recent headlines provide market-context rather than company-specific catalysts. On November 13, 2026, 247wallst.com published “A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer,” a reminder that elevated yields in defensive sectors can sometimes reflect investor concern rather than pure income opportunity. On November 12, 2026, defenseworld.net reported that Commonwealth Equity Services LLC acquired Clorox shares, a routine institutional filing that nonetheless tracks 13F-level positioning. On November 11, 2026, Schaeffer’s Investment Research noted a broad tech rally that lifted the Nasdaq 464 points, a macro backdrop that can shift sector rotation away from staples. On November 9, 2026, The Motley Fool listed Clorox among “3 Magnificent High-Yield Dividend Stocks to Buy Near Their 52-Week Lows,” again framing the stock through an income-and-value lens.

Earnings behavior & post-earnings drift

Clorox has beaten earnings expectations in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 11.1%. The average 5-day price move after earnings across those same quarters is +7.03%, classified as an upward post-earnings drift. That means the stock has tended to reprice higher in the days following reports, even though headline reactions have been uneven.

The last four quarters illustrate the dispersion. On November 2, 2026, Clorox reported EPS of $1.55 against an estimate of $1.07, a 44.9% surprise; the stock rose 4.34% the next day and 17.39% over the following five sessions. On August 3, 2026, EPS of $1.66 edged past the $1.64 estimate by 1.2%, producing a 6.52% one-day jump and a 9.61% five-day gain. The April 30, 2026 report was a beat on the headline—$1.64 versus $1.55, a 5.8% surprise—but the market sold it off sharply, down 9.67% the next day and 4.49% over the next five days. The February 3, 2026 quarter was a miss: EPS of $1.39 versus $1.43, a -2.8% surprise, yet the stock still climbed 2.43% the next day and 5.63% over five days.

Looking ahead, Clorox is scheduled to report again on February 2, 2027 after the close, with the consensus EPS estimate at $0.984. At the current snapshot, the stock is at $109.46, the RSI is 82.6, and the 50-day EMA is $93.18. The next EPS estimate is notably below the $1.55 posted in the most recent quarter, which may reflect seasonal patterns, continued macro pressure, or the timing of the GOJO integration and ERP work.

Frequently Asked Questions

Why is Clorox’s ROE reported as -1,920.6%?

The extreme negative ROE is almost certainly a balance-sheet artifact rather than evidence of massive operating losses, because Clorox’s net margin is still positive at 9.4%. When shareholders’ equity turns negative—from accumulated losses, buybacks, or liability restructuring—the ROE calculation flips to a large negative number even if the company is profitable. For Clorox, P/E and margin are more useful gauges than book-value-based returns right now.

How has the stock typically behaved after earnings?

Over the last eight quarters, Clorox has beaten earnings 75% of the time with an average surprise of 11.1%. The average five-day post-earnings move has been +7.03%, classified as upward drift. However, individual quarters vary widely: the November 2026 report added 17.39% over five days, while the April 2026 report dropped the stock 9.67% the next day despite a beat.

What are Clorox’s main strategic priorities?

Clorox’s 10-K highlights the IGNITE strategy, focused on profitable growth, consumer innovation, reimagining its workforce, and portfolio evolution. Near-term priorities include completing a new ERP and digital transformation, integrating the April 2026 GOJO acquisition, expanding the health and hygiene business, and managing customer concentration (Walmart alone represented 26% of FY2026 net sales).

For a deeper understanding of how sell-side and institutional models view these factors, it is worth reviewing the full institutional verdict on Clorox rather than relying on headline numbers alone.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 16, 2026
The Clorox Company · Consumer Defensive / Household & Personal Products
$13.3BMarket cap
19.7P/E
9.4%Net margin
-1920.6%ROE
75%Beat rate, last 8Q
11.1%Avg EPS surprise
7.03%Avg 5-day move after earnings
2027-02-02Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-02$1.55$1.07+44.9%+4.34%+17.39%
2026-08-03$1.66$1.64+1.2%+6.52%+9.61%
2026-04-30$1.64$1.55+5.8%-9.67%-4.49%
2026-02-03$1.39$1.43-2.8%+2.43%+5.63%
2025-11-03$0.85$0.818+3.9%--
2025-07-31$2.87$2.2+30.5%--

Previous CLX editions

Beyond the primer

Get the institutional verdict on CLX

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the CLX verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.